Table 4.
Model | eGFR | Ln-UAE | LGI | ED | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
β | 95% CI | p value | β | 95% CI | p value | β | 95% CI | p value | β | 95% CI | p value | |
MMP-1 | ||||||||||||
1 | −4.15 | −6.58; −1.73 | 0.001 | −0.01 | −0.13; 0.11 | 0.912 | 0.14 | 0.02; 0.25 | 0.017 | −0.07 | −0.18; 0.05 | 0.249 |
2 | −2.90 | −5.22; −0.57 | 0.015 | −0.03 | −0.14; 0.08 | 0.588 | 0.11 | 0.00; 0.22 | 0.045 | −0.12 | −0.23; −0.01 | 0.031 |
MMP-2 | ||||||||||||
1 | −11.9 | −14.27; −9.56 | <0.001 | 0.29 | 0.16; 0.41 | <0.001 | −0.02 | −0.14; 0.10 | 0.770 | 0.06 | −0.06; 0.18 | 0.333 |
2 | −10.1 | −12.48; −7.64 | <0.001 | 0.19 | 0.07; 0.32 | 0.002 | 0.02 | −0.11; 0.15 | 0.759 | 0.07 | −0.06; 0.19 | 0.318 |
MMP-3 | ||||||||||||
1 | −12.6 | −15.37; −9.92 | <0.001 | 0.28 | 0.13; 0.42 | <0.001 | 0.02 | −0.12; 0.16 | 0.779 | 0.02 | −0.12; 0.16 | 0.792 |
2 | −10.3 | −13.05; −7.64 | <0.001 | 0.16 | 0.02; 0.30 | 0.022 | 0.05 | −0.09; 0.19 | 0.513 | 0.02 | −0.12; 0.16 | 0.818 |
MMP-9 | ||||||||||||
1 | −0.72 | −3.13; 1.70 | 0.559 | 0.02 | −0.09; 0.14 | 0.708 | 0.28 | 0.18; 0.39 | <0.001 | 0.05 | −0.06; 0.16 | 0.347 |
2 | −0.14 | −2.56; 2.29 | 0.912 | 0.02 | −0.10; 0.13 | 0.781 | 0.22 | 0.11; 0.33 | <0.001 | −0.03 | −0.15; 0.08 | 0.580 |
MMP-10 | ||||||||||||
1 | −6.45 | −8.70; −4.19 | <0.001 | 0.08 | −0.03; 0.20 | 0.146 | 0.14 | 0.03; 0.25 | 0.010 | 0.13 | 0.03; 0.24 | 0.015 |
2 | −6.18 | −8.32; −4.03 | <0.001 | 0.11 | 0.00; 0.21 | 0.045 | 0.09 | −0.02; 0.19 | 0.104 | 0.09 | −0.02; 0.19 | 0.110 |
TIMP-1 | ||||||||||||
1 | −10.2 | −12.65; −7.82 | <0.001 | 0.26 | 0.14; 0.39 | <0.001 | 0.30 | 0.19; 0.42 | <0.001 | 0.23 | 0.11; 0.35 | <0.001 |
2 | −8.13 | −10.58; −5.68 | <0.001 | 0.17 | 0.05; 0.29 | 0.005 | 0.33 | 0.21; 0.45 | <0.001 | 0.22 | 0.10; 0.34 | <0.001 |
The standardized regression coefficient β represents the difference in eGFR (in ml/min/1.73 m2), lnUAE (in mg/24 h), LGI (in SD) or ED (in SD) per 1 SD increase in lnMMP-1, -2, -3, -9, and -10 and lnTIMP-1
MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline